Squarepoint
SGNT

Squarepoint’s SAGENT PHARMACEUTICALS INC COM STK (DE) SGNT Stock Holding History

Squarepoint’s Portfolio SGNT Stock Details SGNT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-11,815
Closed -$144K – 1507
2016
Q1 		$144K Buy
11,815
+1,098
+10% +$15.4K 0.01% 1044
2015
Q4 		$171K Buy
+10,717
New +$169K 0.02% 1039

Other funds holding SGNT

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCM
Penn Capital Management Philadelphia, Pennsylvania $1.29B AUM 53.44% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
CC
Carlson Capital Dallas, Texas $318M AUM 27.64% 1-Year Est. Return
NIMC
NWQ Investment Management Company Los Angeles, California $2.22B AUM 6.84% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Squarepoint's SGNT Position: Q2 2016 in Review

Squarepoint sold out of SAGENT PHARMACEUTICALS INC COM STK (DE) (SGNT) in Q2 2016, closing a stake of 11,815 shares — an estimated $144K sold.

Squarepoint first reported a position in SGNT in Q4 2015 and held it in 2 quarters. The position peaked at $171K in Q4 2015. 128 funds tracked by Wall St. Rank hold SGNT as of Q2 2016.

  • Squarepoint reported no remaining SAGENT PHARMACEUTICALS INC COM STK (DE) position as of Q2 2016 after selling out during the quarter.
  • Squarepoint sold 11,815 SAGENT PHARMACEUTICALS INC COM STK (DE) shares in Q2 2016, an estimated $144K.
  • Squarepoint first reported a position in SAGENT PHARMACEUTICALS INC COM STK (DE) in Q4 2015 and held it in 2 quarters.
  • Squarepoint's SAGENT PHARMACEUTICALS INC COM STK (DE) position peaked at $171K in Q4 2015.
  • 128 funds tracked by Wall St. Rank held SAGENT PHARMACEUTICALS INC COM STK (DE) as of Q2 2016.

Based on Squarepoint's 13F filing for Q2 2016, filed 15 Aug 2016.